Put Options

14 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q3 2022

Sep 21, 2023

SELL
$31.97 - $49.37 $316,503 - $488,763
-9,900 Reduced 66.44%
5,000 $162,000
Q3 2022

Nov 14, 2022

BUY
$31.97 - $49.37 $159,850 - $246,850
5,000 New
5,000 $162,000
Q1 2022

May 16, 2022

SELL
$57.56 - $82.54 $857,644 - $1.23 Million
-14,900 Closed
0 $0
Q4 2021

Sep 21, 2023

BUY
$72.5 - $100.68 $319,000 - $442,992
4,400 Added 41.9%
14,900 $1.16 Million
Q4 2021

Feb 14, 2022

BUY
$72.5 - $100.68 $319,000 - $442,992
4,400 Added 41.9%
14,900 $1.16 Million
Q3 2021

Sep 21, 2023

SELL
$90.24 - $124.05 $11.6 Million - $15.9 Million
-128,400 Reduced 92.44%
10,500 $1 Million
Q3 2021

Nov 15, 2021

SELL
$90.24 - $124.05 $11.6 Million - $15.9 Million
-128,400 Reduced 92.44%
10,500 $1 Million
Q1 2021

Sep 21, 2023

BUY
$116.57 - $155.01 $15.6 Million - $20.8 Million
133,900 Added 2678.0%
138,900 $18.3 Million
Q1 2021

May 14, 2021

BUY
$116.57 - $155.01 $15.6 Million - $20.8 Million
133,900 Added 2678.0%
138,900 $18.3 Million
Q1 2020

May 15, 2020

SELL
$37.9 - $104.44 $5.61 Million - $15.5 Million
-148,100 Reduced 96.73%
5,000 $290,000
Q4 2019

Feb 13, 2020

BUY
$77.66 - $99.74 $388,300 - $498,700
5,000 Added 3.38%
153,100 $14.2 Million
Q2 2019

Aug 14, 2019

BUY
$89.51 - $118.04 $10.6 Million - $13.9 Million
118,100 Added 393.67%
148,100 $17.5 Million
Q1 2019

May 15, 2019

BUY
$61.98 - $96.5 $1.56 Million - $2.43 Million
25,200 Added 525.0%
30,000 $2.6 Million
Q4 2018

Feb 14, 2019

BUY
$56.04 - $82.66 $268,992 - $396,768
4,800 New
4,800 $303,000

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $10.7B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Jefferies Group LLC Portfolio

Follow Jefferies Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jefferies Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jefferies Group LLC with notifications on news.